FAYETTEVILLE, GA, UNITED STATES, February 7, 2026 /EINPresswire.com/ -- Accurately isolating individual cells from ...

Patients with concurrent malignancies pose significant diagnostic and therapeutic challenges. We report a rare and fatal case of synchronous ovarian mixed germ cell tumor and mast cell leukemia (MCL) ...

A significantly greater percentage of patients treated with mitapivat achieved hemoglobin response compared with those who received placebo. Topline results were announced from a phase 3 trial ...

Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraise that will enrich the biotech’s ongoing trial of a regenerative cell therapy for Parkinson’s disease. The ...

Researchers discovered a way to keep T cells from wearing out during the fight against cancer, and the approach could make immune-based treatments far more powerful. They found that tumors use a ...

Nov 19 (Reuters) - Agios Pharmaceuticals (AGIO.O), opens new tab said on Wednesday its sickle cell disease drug met one of its two main goals in a late-stage study of patients aged 16 and older but ...

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its commercial outlook and the company’s reinvention. Uptake for the genetic ...

This year, Big Pharma has been active on the M&A front in cell and gene therapy (CGT), with AbbVie setting down $2.1 billion for Capstan Therapeutics’ novel CAR T therapies, Eli Lilly dropping $1.3 ...

In a new study published in Nature Communications titled, “The reference genome of the human diploid cell line RPE-1,” researchers from University of Rome La Sapienza have produced the first reference ...